{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T01:56:48Z","timestamp":1784339808881,"version":"3.55.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2004,7]]},"DOI":"10.1016\/j.maturitas.2003.12.006","type":"journal-article","created":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T05:50:20Z","timestamp":1083390620000},"page":"179-192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Postmenopausal osteoporosis and alendronate"],"prefix":"10.1016","volume":"48","author":[{"given":"Faustino R.","family":"P\u00e9rez-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.maturitas.2003.12.006_BIB1","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1136\/bmj.324.7342.886","article-title":"Selling sickness: the pharmaceutical industry and disease mongering. Medicalisation of risk factors","volume":"324","author":"Moynihan","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.maturitas.2003.12.006_BIB2","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1136\/bmj.324.7349.1342","article-title":"Marketing: celebrity selling","volume":"324","author":"Moynihan","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.maturitas.2003.12.006_BIB3","doi-asserted-by":"crossref","unstructured":"Rapid responses to Moynihan et al. 2002. http:\/\/www.bmj.com\/cgi\/eletters\/324\/7342\/886.","DOI":"10.1136\/bmj.324.7342.886"},{"key":"10.1016\/j.maturitas.2003.12.006_BIB4","unstructured":"Anderson ME. Putting the record straight. http:\/\/www.bmj.com\/cgi\/eletters\/324\/7349\/1342#23332."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1210\/edrv.23.3.0464","article-title":"Genetics of osteoporosis","volume":"23","author":"Peacock","year":"2002","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB6","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1210\/edrv.23.3.0465","article-title":"Sex steroids and the construction and conservation of the adult skeleton","volume":"23","author":"Riggs","year":"2002","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB7","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s001980070075","article-title":"Risk of mortality following clinical fractures","volume":"11","author":"Cauley","year":"2000","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB8","unstructured":"National Osteoporosis Foundation. 1996 and 2015 Osteoporosis prevalence figures. State-by-State Report. Washington, DC: National Osteoporosis Foundation; 1997. Executive summary, 1, 2."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB9","unstructured":"American Cancer Society. Cancer facts & figures-1996. Atlanta (GA): American Cancer Society; 1996. p. 11."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB10","unstructured":"American Heart Association. 1997 Heart and stroke statistical update, vol. 11. Dallas (TX): American Heart Association; 1996. p. 14."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB11","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jama.285.3.320","article-title":"Risk of new vertebral fracture in the year following a fracture","volume":"285","author":"Lindsay","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2003.12.006_BIB12","unstructured":"Ott S. Osteoporosis and bone physiology. World Health Organizations definitions. [http:\/\/www.uwcme.org\/courses\/bonephys\/whodef.html]."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB13","unstructured":"National Osteoporosis Foundation. Physician\u2019s guide to prevention and treatment of osteoporosis. Belle Mead (NJ): Excerpta Medica; 1999."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB14","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1067\/mob.2000.106594","article-title":"Identification of at-risk women for osteoporosis screening","volume":"183","author":"Weinstein","year":"2000","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB15","first-page":"509","article-title":"Decision rules for bone mineral density testing","volume":"167","author":"Kovacs","year":"2002","journal-title":"CMAJ"},{"key":"10.1016\/j.maturitas.2003.12.006_BIB16","first-page":"37","article-title":"Development and validation of a simple questionnaire to facilitate identification of women likely to have low bone density","volume":"4","author":"Lydick","year":"1998","journal-title":"Am. J. Manage. Care"},{"key":"10.1016\/j.maturitas.2003.12.006_BIB17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jama.286.1.57","article-title":"Evaluation of decision rules for referring women for bone densitometry by dual-energy X-ray absorptiometry","volume":"286","author":"Cadarette","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2003.12.006_BIB18","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/BF01623934","article-title":"Screening for osteopenia and osteoporosis: selection by body composition","volume":"6","author":"Micha\u00eblsson","year":"1996","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB19","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-137-6-200209170-00015","article-title":"Screening for postmenopausal osteoporosis: a review of the evidence for the US Preventive Services Task Force","volume":"137","author":"Nelson","year":"2002","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB20","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1210\/jcem.85.1.6267","article-title":"Antifracture efficacy of antiresorptive agents are related to changes in bone density","volume":"85","author":"Wasnich","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB21","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/bmj.321.7258.396","article-title":"The increasing use of peripheral bone densitometry","volume":"321","author":"Masud","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.maturitas.2003.12.006_BIB22","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1210\/jcem.87.6.8575","article-title":"MK-063 Study Group. Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women","volume":"87","author":"Bell","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB23","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1046\/j.1532-5415.2002.50102.x","article-title":"FIT Research Group. Alendronate reduces the risk of multiple symptomatic fractures: results from the Fracture Intervention Trial","volume":"50","author":"Levis","year":"2002","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB24","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S8756-3282(97)00170-1","article-title":"Bone mineral density reflects bone mass but also the degree of mineralization of bone: therapeutic implications","volume":"21","author":"Meunier","year":"2000","journal-title":"Bone"},{"key":"10.1016\/j.maturitas.2003.12.006_BIB25","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/bmj.312.7041.1254","article-title":"Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures","volume":"312","author":"Marshall","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.maturitas.2003.12.006_BIB26","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s001980050061","article-title":"How hip and whole body bone mineral density predict hip fracture in elderly woman: the EPIDOS prospective study","volume":"8","author":"Schott","year":"1998","journal-title":"Osteoporosis Int."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB27","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1359\/jbmr.2000.15.2.183","article-title":"Bone matters: are density increases necessary to reduce fracture risk?","volume":"15","author":"Faulkner","year":"2000","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB28","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/jcem.87.4.8415","article-title":"Changes in bone density and turnover explain the reduction in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents","volume":"87","author":"Hochberg","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB29","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S8756-3282(00)00376-8","article-title":"Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women","volume":"27","author":"Boivin","year":"2000","journal-title":"Bone"},{"key":"10.1016\/j.maturitas.2003.12.006_BIB30","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1210\/er.2001-2002","article-title":"II. Meta-analysis of alendronate for the treatment of postmenopausal women","volume":"23","author":"Cranney","year":"2002","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB31","unstructured":"P\u00e9rez-L\u00f3pez FR. Alendronato y tratamiento hormonal sustitutivo en la osteoporosis femenina. In: P\u00e9rez-L\u00f3pez FR, editor. Climaterio y envejecimiento. Medicina basada en la evidencia. Zaragoza: SEISGE; 1999. p. 273\u201392."},{"issue":"Suppl","key":"10.1016\/j.maturitas.2003.12.006_BIB32","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/00007611-199208001-00006","article-title":"Bisphosphonates therapy for postmenopausal osteoporosis","volume":"85","author":"Watts","year":"1992","journal-title":"South Med."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB33","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1177\/00912709922008272","article-title":"Developments in the therapeutic applications of biphosphonates","volume":"39","author":"Brown","year":"1999","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB34","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1517\/14656566.1.2.225","article-title":"Bisphosphonates in osteoporosis: recent clinical experience","volume":"1","author":"McClung","year":"2001","journal-title":"Exp. Opin. Pharmacother."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB35","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2165\/00003495-199753030-00006","article-title":"Alendronate: a review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis","volume":"53","author":"Jeal","year":"1997","journal-title":"Drugs"},{"key":"10.1016\/j.maturitas.2003.12.006_BIB36","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1172\/JCI6800","article-title":"Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin","volume":"104","author":"Plotkin","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB37","first-page":"720","article-title":"Alendronate and estrogen effects in postmenopausal women with low dose bone mineral density","volume":"85","author":"Bone","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF03339822","article-title":"Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis","volume":"12","author":"Schnitzer","year":"2000","journal-title":"Aging Clin. Exp. Res."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB39","first-page":"3109","article-title":"Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women","volume":"85","author":"Tonino","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB40","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1359\/jbmr.2002.17.11.1988","article-title":"Two year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis","volume":"17","author":"Rizzoli","year":"2002","journal-title":"J. Bone Miner Res."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB41","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten-year experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"New Engl J Med."},{"issue":"Suppl 2","key":"10.1016\/j.maturitas.2003.12.006_BIB42","first-page":"S372","article-title":"Alendronate increases trabecular bone connectivity in elderly osteoporotic women","volume":"18","author":"Masarachia","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB43","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1359\/jbmr.2000.15.4.613","article-title":"Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib","volume":"15","author":"Mashiba","year":"2000","journal-title":"J. Bone Miner Res."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB44","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S8756-3282(01)00575-0","article-title":"Effects of high-dose etidronate treatment on microdamage accumulation and biomechanical properties in beagle bone before occurrence of spontaneous fractures","volume":"29","author":"Mashiba","year":"2001","journal-title":"Bone"},{"key":"10.1016\/j.maturitas.2003.12.006_BIB45","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S8756-3282(02)00946-8","article-title":"Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience","volume":"32","author":"Sorensen","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.maturitas.2003.12.006_BIB46","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","article-title":"Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study","volume":"9","author":"Pols","year":"1999","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB47","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2003.12.006_BIB48","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2003.12.006_BIB49","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0889-8529(05)70014-1","article-title":"Treatment of osteoporosis with bisphosphonates","volume":"27","author":"Watts","year":"1998","journal-title":"Endocrinol. Metab. Clin. N. Amer."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB50","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","article-title":"Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial","volume":"85","author":"Black","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB51","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/1529-0131(199906)42:6<1246::AID-ANR22>3.0.CO;2-U","article-title":"Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis: Fracture Intervention Trial Research Group","volume":"42","author":"Hochberg","year":"1999","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB52","doi-asserted-by":"crossref","first-page":"935","DOI":"10.7326\/0003-4819-131-12-199912210-00005","article-title":"Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the Early Postmenopausal Intervention Cohort Study: a randomized trial","volume":"131","author":"Ravn","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB53","first-page":"1492","article-title":"Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group","volume":"85","author":"Ravn","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB54","first-page":"711","article-title":"Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis","volume":"101","author":"Luckey","year":"2003","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2003.12.006_BIB55","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2165\/00002018-200225110-00003","article-title":"Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review","volume":"25","author":"Kherani","year":"2002","journal-title":"Drug. Saf."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB56","doi-asserted-by":"crossref","first-page":"230","DOI":"10.12968\/hosp.2002.63.4.2043","article-title":"Once-weekly treatment for osteoporosis","volume":"63","author":"Stone","year":"2002","journal-title":"Hosp. Med."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB57","unstructured":"Izarra P\u00e9rez L, Medrano Sanidefonso M, Paleo ME, the members of the Satisfaction, Preference and Compliance with Biphosphonates Study Group. Satisfaction, preference and compliance with alendronate and risedronate in postmenopausal women with osteoporosis. In: Proceedings of the Third International Meeting on Social and Economic Aspects of Osteoporosis and Osteoarthritis, Barcelona, 7\u20139 noviembre 2002. abstract 0110\/2."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB58","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.4065\/77.10.1044","article-title":"Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study","volume":"77","author":"Greenspan","year":"2002","journal-title":"Mayo. Clin. Proc."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB59","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00198-003-1399-y","article-title":"Pharmacovigilance study of alendronate in England","volume":"14","author":"Biswas","year":"2003","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB60","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1210\/edrv.23.1.0453","article-title":"Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint","volume":"23","author":"Marcus","year":"2002","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB61","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1001\/jama.285.22.2891","article-title":"Hormone replacement therapy and prevention of non-vertebral fractures: a metaanalysis of randomised trials","volume":"285","author":"Torgerson","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2003.12.006_BIB62","doi-asserted-by":"crossref","unstructured":"Writing group for the Women\u2019s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women, JAMA 2002;288:321\u201333.","DOI":"10.1001\/jama.288.3.321"},{"key":"10.1016\/j.maturitas.2003.12.006_BIB63","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1185\/030079903125002009","article-title":"Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study","volume":"19","author":"Hosking","year":"2003","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB64","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S8756-3282(95)00262-6","article-title":"Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis","volume":"17","author":"Adami","year":"1995","journal-title":"Bone"},{"key":"10.1016\/j.maturitas.2003.12.006_BIB65","first-page":"1783","article-title":"Comparison of alendroante and intranasal calcitonin for treatment of osteoporosis in postmenopausal women","volume":"85","author":"Downs","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB66","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1210\/jcem.86.10.7937","article-title":"Prevention of bone loss with tibolone in postmenopausal women (2002) results of two randomized, double-blind, placebo-controlled, dose-finding studies","volume":"86","author":"Gallagher","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB67","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/archinte.162.6.665","article-title":"Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen\/Progestin Interventions (PEPI) Safety Follow-up Study","volume":"162","author":"Greendale","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.maturitas.2003.12.006_BIB68","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1046\/j.1365-2265.2002.01534.x","article-title":"Prospective 10-year study of the determinants of bone density and bone loss in normal postmenopausal women, including the effect of hormone replacement therapy","volume":"56","author":"Wu","year":"2002","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB69","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0025-7753(03)73630-6","article-title":"Tratamiento hormonal de la menopausia: controversias, precisiones y perspectivas","volume":"120","author":"P\u00e9rez-L\u00f3pez","year":"2003","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.maturitas.2003.12.006_BIB70","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0002-9343(98)00029-1","article-title":"A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis","volume":"104","author":"Wimalawansa","year":"1998","journal-title":"Am. J. Med."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB71","first-page":"3076","article-title":"Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial","volume":"84","author":"Lindsay","year":"1999","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB72","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1210\/jcem.87.4.8323","article-title":"Effect of estrogen replacement plus low-dose alendronate treatment on bone density in surgically postmenopausal women with osteoporosis","volume":"87","author":"Palomba","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB73","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1210\/jcem.87.3.8325","article-title":"Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis","volume":"87","author":"Johnell","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2003.12.006_BIB74","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archinte.163.7.789","article-title":"Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial","volume":"163","author":"Ascott-Evans","year":"2003","journal-title":"Arch. Intern. Med."}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512204000052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512204000052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T08:37:35Z","timestamp":1759912655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512204000052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7]]},"references-count":74,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["S0378512204000052"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2003.12.006","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2004,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Postmenopausal osteoporosis and alendronate","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2003.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}